Regular ArticleNon-neuronal induction of immunoproteasome subunits in an ALS model: Possible mediation by cytokines
Introduction
Mutations in the Cu, Zn superoxide dismutase (SOD1) gene cause one form of familial amyotrophic lateral sclerosis (FALS) via a gain in function that may be related to abnormal SOD1 protein processing and aggregation (Rosen et al., 1993). Indeed, the presence of SOD1 aggregates within the CNS is a pathologic hallmark of disease both in humans dying from SOD1-related FALS and in transgenic mice expressing various SOD1 mutations (Gurney et al., 1994, Watanabe et al., 2001, Shibata et al., 1996, Bruijn et al., 1998, Wang et al., 2002a, Wong et al., 1995). The accumulation of SOD1 aggregates begins early in the lifespan of mutant SOD1 transgenic mice, clearly preceding the onset of motor dysfunction and consistent with having a primary role in the disease process (Wang et al., 2002b). Moreover, the tissue distribution of SOD1 aggregates in vivo is strikingly limited to those regions clearly affected by the disease, including brain and spinal cord, but is absent from ALS-resistant organs such as liver or kidney, despite their having overall higher mutant SOD1 expression levels (Wang et al., 2002b, Puttaparthi et al., 2003). SOD1 aggregates can readily be visualized either as cytoplasmic inclusions or as high molecular weight protein complexes (HMWPCs) on Western blots (Wang et al., 2002b, Johnston et al., 2000, Kato et al., 1997, Bruijn et al., 1997, Wang et al., 2003).
Several studies have clearly demonstrated that proteasome-mediated degradation pathways are responsible for clearing SOD1 aggregates from a variety of differing cell types including intact murine spinal cord (Puttaparthi et al., 2003, Johnston et al., 2000, Urushitani et al., 2002, Hyun et al., 2003). The 26S proteasome is composed of one 20S proteolytic complex and two axially positioned 19S (PA700) regulatory complexes (DeMartino and Slaughter, 1999). The 20S complex is itself composed of 2 copies each of 7 α and β type subunits, each encoded by distinct genes. Each β ring contains three differing proteolytic sites that differ in its specificity including a chymotrypsin-like site that cleaves after hydrophobic residues, a trypsin-like site that cleaves after basic residues and a post-glutamyl peptide hydrolase or caspase-like activity that cuts after the acidic residues glutamate and aspartate (Kisselev et al., 2003). Certain β subunits of the 20S core appear to be inducible and convey differing proteolytic function on the proteasome. Inducible β subunits such as LMP2, MECL-1 and LMP7 can replace the normal constitutive β1, β2 and β5 subunits and have recently been shown to be increased in Huntington's disease (Diaz-Hernandez et al., 2003, Fabunmi et al., 2001, Rivett and Hearn, 2004). It is unknown whether inducible proteasomes, also known as immunoproteasomes, possess a capacity to degrade disease related aggregates that is distinct from constitutive proteasomes.
Pre-formed SOD1 aggregates within mouse spinal cord can be cleared by enhancing proteasomal function, suggesting that the accumulation of SOD1 aggregates within the CNS is a reversible phenomenon potentially dependent on equilibrium between aggregate formation and clearance via proteasomes (Puttaparthi et al., 2003). In certain experimental conditions, protein aggregates themselves may directly impair proteasome function leading to a vicious cycle that favors even greater aggregate accumulation (Bence et al., 2001). Alternatively, potentially representing a cellular attempt to improve protein degradation capability, proteasome induction has been observed within certain human degenerative diseases characterized by prominent aggregates including Huntington's and inclusion body myopathies (Diaz-Hernandez et al., 2003, Ferrer et al., 2004). Therefore, we sought to determine whether proteasome function is altered within the spinal cord of mutant SOD1 transgenic mice as aggregates accumulate, and if so what is the potential mechanism of that change?
Section snippets
Animals
Transgenic mice expressing the low copy number human G93A SOD1 mutation (B6SJL-TgNSOD1-G93A; JR2300) were originally obtained from The Jackson Laboratory (Bar Harbor, ME). These mice have a mean survival of 250 days with the onset of motor dysfunction beginning at 5.5–6 months of age (Puttaparthi et al., 2002). Transgenic mice expressing wild type human SOD1 (B6SJL WT-SOD1; Jackson Laboratory) were used as controls for increased SOD1 production. All animal protocols were approved by our
Induction of proteasome activity in G93A SOD1 spinal cord
In order to assess the effect of mutant SOD1-induced disease on proteasome function, we measured proteasome activity in the spinal cord of transgenic mice expressing a G93A SOD1 mutation. At 7.5 months of age, these mice exhibit marked motor deficits in both fore and hind limbs, with prominent aggregate accumulation (both inclusion bodies and HMWPCs) noted in the spinal cord. For controls, we measured proteasome function in age-matched non-transgenic littermates and in transgenic mice
Discussion
The presence of SOD1-positive aggregates within the CNS is a pathologic hallmark of disease in both transgenic mice expressing mutant SOD1 and humans with FALS caused by SOD1 mutations. Although the actual role of SOD1 protein aggregates in contributing to the FALS disease phenotype is unknown, there exists a perfect correlation between the disease state and aggregate accumulation. The presence of SOD1 aggregates is a highly sensitive and specific marker of this particular FALS and consistent
Acknowledgments
We would like to thank Bhagya Rajendran and Jill Marshall for technical assistance. This work was supported by the NINDS (NS40911) and by the Horace Cabe Foundation.
References (50)
- et al.
ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions
Neuron
(1997) - et al.
Altered properties of the branched chain amino acid-preferring activity contribute to increased cleavages after branched chain residues by the “immunoproteasome”
J. Biol. Chem.
(1998) - et al.
Accumulation of human SOD1 and ubiquitinated deposits in the spinal cord of SOD1G93A mice during motor neuron disease progression correlates with a decrease of proteasome
Neurobiol. Dis.
(2005) - et al.
The proteasome, a novel protease regulated by multiple mechanisms
J. Biol. Chem.
(1999) - et al.
Identification, purification, and characterization of a PA700-dependent activator of the proteasome
J. Biol. Chem.
(1996) Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis
Brain Res. Mol. Brain Res.
(2001)- et al.
Proteasome subunits X and Y alter peptidase activities in opposite ways to the interferon-gamma-induced subunits LMP2 and LMP7
J. Biol. Chem.
(1996) - et al.
Metallothionein expression is altered in a transgenic murine model of familial amyotrophic lateral sclerosis
Exp. Neurol.
(2000) - et al.
Tumor necrosis factor-alpha induces coordinated changes in major histocompatibility class I presentation pathway, resulting in increased stability of class I complexes at the cell surface
Blood
(2001) - et al.
Message and protein-level elevation of tumor necrosis factor alpha (TNF alpha) and TNF alpha-modulating cytokines in spinal cords of the G93A-SOD1 mouse model for amyotrophic lateral sclerosis
Neurobiol. Dis.
(2003)
The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites
J. Biol. Chem.
Loss of an individual proteasome subunit alters motor function but not cognitive function or ambulation in mice
Neurosci. Lett.
Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice
J. Biol. Chem.
cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome
J. Biol. Chem.
Transforming growth factor-beta1 induces transforming growth factor-beta1 and transforming growth factor-beta receptor messenger RNAs and reduces complement C1qB messenger RNA in rat brain microglia
Neuroscience
Assessment of proteasomal cleavage probabilities from kinetic analysis of time-dependent product formation
J. Mol. Biol.
Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis
J. Neurol. Sci.
Relative functions of the alpha and beta subunits of the proteasome activator, PA28
J. Biol. Chem.
Fibrillar inclusions and motor neuron degeneration in transgenic mice expressing superoxide dismutase 1 with a disrupted copper-binding site
Neurobiol. Dis.
High molecular weight complexes of mutant superoxide dismutase 1: age-dependent and tissue-specific accumulation
Neurobiol. Dis.
Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues
Neurobiol. Dis.
An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria
Neuron
Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis
J. Neurochem.
Impairment of the ubiquitin–proteasome system by protein aggregation
Science
Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1
Science
Cited by (51)
Deficiency of the immunoproteasome subunit β5i/LMP7 supports the anxiogenic effects of mild stress and facilitates cued fear memory in mice
2019, Brain, Behavior, and ImmunityEndoplasmic reticulum stress and proteasomal system in amyotrophic lateral sclerosis
2015, Free Radical Biology and MedicineCitation Excerpt :The α subunit levels were also decreased in the same study, inducing the loss of cellular proteasome in ALS. Moreover, the immunoproteasome was affected in the nonneuronal model of ALS, which was confirmed by an increase in β5i subunit and PA28 in astrocytes and glial cells of the spinal cord [120]. Nrf2 is the transcription factor for the synthesis of antioxidant proteins and also proteasomes, which may suggest the attempt to upregulate these systems in ALS.
The mammalian target of rapamycin modulates the immunoproteasome system in the heart
2015, Journal of Molecular and Cellular CardiologyCitation Excerpt :In addition, the immunoproteasome associates with regulatory complexes that are different from the constitutive proteasome: the 11S (PA28α/β) complex. The expression of immunoproteasome subunits can be induced by inflammatory cytokines including INFγ and TNFα [21,23–25]. In addition to its role in antigen presentation, the immunoproteasome may play an important role in the degradation of oxidized proteins, during oxidative stress and inflammation [26–29].
Modeling motor neuron disease: The matter of time
2014, Trends in NeurosciencesProteasome activation delays aging in vitro and in vivo
2014, Free Radical Biology and MedicineCitation Excerpt :Cheroni and colleagues [276] also reported a decrease in constitutive proteasome subunits and increase in immunoproteasome expression after a local inflammatory response due to glial activation in the SOD1G93A transgenic ALS mice [276]. The spinal cord of the same ALS mouse model exhibited increased proteasome activities and elevated expression levels of all βi subunits in astrocytes and microglia [277]. Neuroinflammatory processes associated with aging were also shown to contribute to increased immunoproteasome/proteasome ratio in aged rat hippocampus.